41.22
Staar Surgical Co. stock is currently priced at $41.22, with a 24-hour trading volume of 268.80K.
It has seen a -1.65% decreased in the last 24 hours and a -5.57% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $41.78 pivot point. If it approaches the $40.74 support level, significant changes may occur.
Previous Close:
$41.91
Open:
$41.41
24h Volume:
268.80K
Market Cap:
$2.03B
Revenue:
$322.42M
Net Income/Loss:
$21.35M
P/E Ratio:
105.69
EPS:
0.39
Net Cash Flow:
$-3.59M
1W Performance:
+6.62%
1M Performance:
-5.57%
6M Performance:
+16.74%
1Y Performance:
-18.34%
Staar Surgical Co. Stock (STAA) Company Profile
Name
Staar Surgical Co.
Sector
Industry
Phone
626-303-7902
Address
1911 Walker Avenue, Monrovia, CA
Staar Surgical Co. Stock (STAA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-11-24 | Upgrade | Stifel | Hold → Buy |
Dec-05-23 | Downgrade | Needham | Buy → Hold |
Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
Sep-15-23 | Downgrade | The Benchmark Company | Buy → Hold |
Aug-03-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Jun-07-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Apr-17-23 | Initiated | Piper Sandler | Neutral |
Feb-06-23 | Downgrade | BTIG Research | Buy → Neutral |
Dec-28-22 | Reiterated | BTIG Research | Buy |
Dec-08-22 | Initiated | Stifel | Hold |
Nov-07-22 | Upgrade | Sidoti | Neutral → Buy |
Oct-14-22 | Resumed | Stephens | Overweight |
Oct-13-22 | Initiated | Mizuho | Buy |
Apr-08-22 | Initiated | Needham | Buy |
Mar-28-22 | Upgrade | The Benchmark Company | Hold → Buy |
Mar-18-22 | Upgrade | BTIG Research | Neutral → Buy |
Jul-09-21 | Initiated | Oppenheimer | Perform |
Jan-19-21 | Downgrade | The Benchmark Company | Buy → Hold |
Oct-26-20 | Downgrade | Sidoti | Buy → Neutral |
Aug-31-20 | Upgrade | Sidoti | Neutral → Buy |
Aug-06-20 | Reiterated | The Benchmark Company | Buy |
Jul-06-20 | Downgrade | Sidoti | Buy → Neutral |
Jun-24-20 | Downgrade | BTIG Research | Buy → Neutral |
Jun-15-20 | Initiated | Jefferies | Buy |
Dec-04-19 | Initiated | BTIG Research | Buy |
Sep-24-18 | Reiterated | The Benchmark Company | Buy |
Aug-06-18 | Resumed | The Benchmark Company | Buy |
Nov-20-17 | Reiterated | The Benchmark Company | Buy |
Aug-14-17 | Reiterated | The Benchmark Company | Buy |
Mar-03-17 | Reiterated | The Benchmark Company | Buy |
May-18-16 | Upgrade | The Benchmark Company | Hold → Buy |
Sep-10-13 | Resumed | The Benchmark Company | Buy |
Feb-28-13 | Reiterated | The Benchmark Company | Buy |
Nov-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
Mar-02-12 | Initiated | Northland Securities | Outperform |
Oct-25-11 | Reiterated | The Benchmark Company | Buy |
Oct-12-10 | Initiated | Morgan Joseph | Buy |
May-11-10 | Initiated | Benchmark | Buy |
View All
Staar Surgical Co. Stock (STAA) Latest News
A company insider recently bought 1 shares of Staar Surgical Co. [STAA]. Should You Buy? – Knox Daily - Knox Daily
Knox Daily
Staar Surgical Co. Inc. (STAA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
The InvestChronicle
STAAR Surgical (NASDAQ:STAA) Shares Purchased by Broadwood Capital Inc. - MarketBeat
MarketBeat
Broadwood Capital Inc. Has $328.89 Million Position in STAAR Surgical (NASDAQ:STAA) - Defense World
Defense World
New Strong Buy Stocks for October 7th - Yahoo Movies UK
Yahoo Movies UK
STAAR Surgical: Keeping An Eye On The Shares (NASDAQ:STAA) - Seeking Alpha
Seeking Alpha
Staar Surgical Co. Stock (STAA) Financials Data
Staar Surgical Co. (STAA) Revenue 2024
STAA reported a revenue (TTM) of $322.42 million for the quarter ending December 31, 2023, a +13.37% rise year-over-year.
Staar Surgical Co. (STAA) Net Income 2024
STAA net income (TTM) was $21.35 million for the quarter ending December 31, 2023, a -46.18% decrease year-over-year.
Staar Surgical Co. (STAA) Cash Flow 2024
STAA recorded a free cash flow (TTM) of -$3.59 million for the quarter ending December 31, 2023, a -120.41% decrease year-over-year.
Staar Surgical Co. (STAA) Earnings per Share 2024
STAA earnings per share (TTM) was $0.43 for the quarter ending December 31, 2023, a -44.87% decline year-over-year.
About Staar Surgical Co.
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in approximately 75 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.
Cap:
|
Volume (24h):